Journals / Türkiye Parazitoloji Dergisi / 2021 / Cilt: 45 - Sayı: 3

Comparison of the New Multiepitope Recombinant Peptide Antigen with Cyst Fluid Antigen in the Follow-up of Patients with Cystic Echinococcosis

Kistik Ekinokokkozisli Hastaların Takibinde Yeni Multiepitop Rekombinant Peptit Antijeninin Kist Sıvısı Antijeni ile Karşılaştırılması

Pages
201–206
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results suggest that imaging methods are gold standards in the diagnosis and that, in parallel, longer-term patient follow-up is required with recombinant antigens that have an improved diagnostic performance.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The follow-up of patients with cystic echinococcosis (CE) offers the opportunity of evaluating the prognosis of the infection as well as detecting relapse.
📊
Key Findings & Data:This study aimed to evaluate the performance of the new multiepitope recombinant peptide (recDipol) antigen in the follow-up of CE patients treated by surgery or percutaneous aspiration injection respiration.
💡
Conclusion & Impact:Our results suggest that imaging methods are gold standards in the diagnosis and that, in parallel, longer-term patient follow-up is required with recombinant antigens that have an improved diagnostic performance.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The follow-up of patients with cystic echinococcosis (CE) offers the opportunity of evaluating the prognosis of the infection as well as detecting relapse. This study aimed to evaluate the performance of the new multiepitope recombinant peptide (recDipol) antigen in the follow-up of CE patients treated by surgery or percutaneous aspiration injection respiration. Methods: A total of 137 blood samples from 28 patients were evaluated by IgG-ELISA method using recDipol and hydatid fluid (HF) antigens. The patients were simultaneously checked for recurrence by ultrasonography. Results: The seropositivity rate of the 28 patients varied considerably during the follow-up. When the first blood of the patients was evaluated, 4 (14.28%) were seronegative by HF-ELISA and 9 (32.14%) were recDipol-ELISA. During the entire follow-up, only 1 (3.5%) and 6 (21.4%) patients were seronegative by HF-ELISA and recDipol ELISA, respectively. Conclusion: We found that recDipol did not perform as expected in the follow-up due to the higher number of seronegative patients compared to HF-ELISA in the first blood and during the entire follow-up. Our results suggest that imaging methods are gold standards in the diagnosis and that, in parallel, longer-term patient follow-up is required with recombinant antigens that have an improved diagnostic performance.

Özet

Amaç: Çalışmada, kistik ekinokokkozisli (KE) hastaların takibi, enfeksiyonun prognozu ve tekrarlayan kistlerin mümkün olan en kısa sürede tespiti konularında değerlendirme imkanı sunulmaktadır. Ayrıca, yeni multiepitop rekombinant peptit (recDipol) antijeninin cerrahi veya perkütan aspirasyon enjeksiyon reaspirasyon işlemi uygulanan KE’li hastaların takibindeki performansının değerlendirilmesi amaçlanmıştır. Yöntemler: Çalışmamızda, 28 KE hastasına ait toplam 137 kan örneği IgG-ELISA yöntemi ile, recDipol ve kist sıvısı (KS) antijenleri kullanılarak değerlendirilmiştir. Hastalar eş zamanlı olarak girişimsel radyoloji bölümünde ultrasonografi ile nüks açısından kontrol edilmiştir. Bulgular: Takip süreleri boyunca 28 takip hastasının seropozitivite oranları aylara göre değişkenlik göstermiştir. Bu hastaların operasyon sırasında alınan kan örnekleri incelendiğinde, 4’ünün (%14,28) KS-ELISA ile, 9’unun (%32,14) recDipol-ELISA ile seronegatif olduğu tespit edilmiştir. Tüm takip süresi boyunca seronegatif hasta sayısı ise KS-ELISA ile 1 (%3,5), recDipol ELISA ile 6 (%21,4) olarak kaydedilmiştir. Sonuç: RecDipol ELISA ile hastalardan ilk tanıda ve tüm takip boyunca alınan kan örneklerinde belirlenen seronegatif hasta sayısının, KS-ELISA ile belirlenenden fazla olması, recDipol antijeninin hasta takibinde beklenen performansı göstermediği şeklinde değerlendirilmiştir. Çalışmada elde edilen bu sonuçlar, KE hastalarının tanısında ve takibinde altın standardın görüntüleme yöntemleri olduğu ve paralelinde tanı performansı geliştirilmiş rekombinant antijenlerle daha uzun süreli hasta takibinin yapılması gerektiği şeklinde yorumlanmıştır.

🔖

Cite This Article

CANER, A., ÜNVER, A., ÖZTÜRK, E. A., AKIL, M., ALTINTAŞ, N., BOZKAYA, H. (2022). Comparison of the New Multiepitope Recombinant Peptide Antigen with Cyst Fluid Antigen in the Follow-up of Patients with Cystic Echinococcosis. Türkiye Parazitoloji Dergisi, Cilt: 45 - Sayı: 3, 201–206. https://ajindex.com/articles/629886

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Altintas N. Past to present: echinococcosis in Turkey. Acta Trop 2003; 85: 105-12
  2. Atkinson JA, Gray DJ, Clements AC, Barnes TS, McManus DP, Yang YR. Environmental changes impacting Echinococcus transmission: research to support predictive surveillance and control. Glob Chang Biol 2013; 19: 677-88. 3. da Silva AM. Human echinococcosis: a neglected disease. Gastroenterol Res Pract 2010; 2010: 583297
  3. Manciulli T, Mariconti M, Vola A, Lissandrin R, Brunetti E. Cystic Echinococcosis in the Mediterranean. Curr Trop Med Reports 2017; 4: 235-44
  4. Engström ELS, Salih GN, Wiese L. Seronegative, complicated hydatid cyst of the lung: A case report. Respir Med Case Rep 2017; 21: 96-98
  5. Akcam AT, Ulku A, Koltas IS, Izol V, Bicer OS, Kilicbagir E, et al. Clinical characterization of unusual cystic echinococcosis in southern part of Turkey. Ann Saudi Med 2014; 34: 508-16
  6. Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114: 1-16
  7. Siracusano A, Teggi A, Ortona E. Human cystic echinococcosis: old problems and new perspectives. Interdiscip Perspect Infect Dis 2009; 2009: 474368
  8. Kabaalioğlu A, Ceken K, Alimoglu E, Apaydin A. Percutaneous imagingguided treatment of hydatid liver cysts: do long-term results make it a first choice? Eur J Radiol 2006; 59: 65-73
  9. Smego Jr RA, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspirationinjection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis Clin Infect Dis 2006; 59: 65-73
  10. Stojkovic M, Zwahlen M, Teggi A, Vutova K, Cretu CM, Virdone R, et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis 2009; 3: e524
  11. Boubaker G, Gottstein B, Hemphill A, Babba H, Spiliotis M. Echinococcus P29 antigen: molecular characterization and implication on post-surgery follow-up of CE patients infected with different species of the Echinococcus granulosus complex. PLoS One 2014; 9: e98357
  12. Brunetti E, Junghanss T. Update on cystic hydatid disease. Curr Opin Infect Dis 2009; 22: 497-502
  13. Ben Nouir N, Nuñez S, Gianinazzi C, Gorcii M, Müller N, Nouri A, et al. Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic echinococcosis. J Clin Microbiol 2008; 46: 1631-40
  14. Nouir NB, Nuñez S, Frei E, G